Mr. Speaker, our government is committed to improving access to necessary prescription drugs and ensuring that products on the Canadian market remain of the highest quality. To that end, our department has recently launched an initiative to improve the regulatory review of drugs and devices. It is a major effort to increase the availability of prescription drugs, including drugs for rare diseases. This initiative will help improve access to the therapeutic products needed to better meet the needs of the health care system.
In the House of Commons on March 20th, 2018. See this statement in context.